Registrant’s telephone number, including area code (650) 366-2626
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 13, 2011, Toby Rosenblatt resigned from his position as a member of the Board of Directors of A.P. Pharma, Inc. (the “Company”), effective April 13, 2011. Mr. Rosenblatt also held the position of Chairman of the Compensation and Stock Option Committee. On April 18, 2011, Robert Zerbe, M.D. resigned from his position as a member of the Board of Directors of the Company. The decisions by Mr. Rosenblatt and Dr. Zerbe did not involve a disagreement with the Company. The continuing board members are Dr. Paul Goddard, Gregory Turnbull and Kevin Tang.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
